Advertising GLP-1 on Meta After the 35-State-AG Action: What Changed in 2026
If you run paid social for a GLP-1 or weight-loss brand, the ground moved under you at the end of 2025. In December, a bipartisan coalition of 35+ state attorneys general publicly pressured Meta to crack down on misleading, AI-generated weight-loss drug ads (per the coalition’s December 2025 letter to Meta), and the FDA issued warning letters to telehealth companies over compounded GLP-1 marketing (per the FDA’s published warning-letter database). The enforcement environment is now the tightest it has ever been - and the brands still scaling are the ones that treated compliance as the strategy, not the afterthought.
Here’s what actually changed, what didn’t, and the exact way compliant GLP-1 brands keep their Meta accounts live in 2026.
Ad policies and enforcement change frequently - verify current requirements directly with Meta before launch. This is practitioner guidance, not legal advice.
What did the 35-state-AG action actually change?
The short version: the written policy didn’t change much - enforcement did. Meta’s Health & Wellness ad standards already prohibited before/after imagery, negative self-perception framing, and marketing compounded GLP-1 as equivalent to the branded drug. What the AG pressure changed is how aggressively that policy is enforced, especially against AI-generated testimonials and misleading claims. Accounts that skated by on borderline creative in early 2025 are getting flagged now.
Two things are worth internalizing:
- AI-generated fake testimonials are now an active enforcement target. The AGs specifically called out AI-fueled weight-loss ads. If your creative uses synthetic “patients” making outcome claims, that’s exactly what’s under the microscope.
- The compounded-GLP-1 window has closed. With the FDA shortages resolved (tirzepatide in December 2024, semaglutide in February 2025) and 503A/503B enforcement deadlines lapsed by mid-2025, mass-market compounded copies are no longer protected. You can’t market them as equivalent to Wegovy or Zepbound.
Can you still advertise GLP-1 on Meta in 2026?
Yes - with real constraints. Naming the prescription drug (semaglutide, tirzepatide, Wegovy, Zepbound) requires active LegitScript certification plus Meta authorization, targeting only the US, Canada, and New Zealand, gated to 18+. Everything about the creative is where brands get burned. For the full breakdown, see our page on advertising GLP-1 on Meta, but the headline rules are:
- No before/after or side-by-side transformation imagery. This is the single fastest route to a rejection and an account-restriction trigger.
- No “lose X lbs,” guaranteed, or rapid-results claims.
- No framing that implies negative self-perception or a “perfect body” ideal - this is quoted policy language.
- No marketing compounded GLP-1 as equivalent to the branded drug.
- No under-18 targeting.
What gets a GLP-1 ad account disabled?
From what we see across accounts, the disablement cascade almost always starts with one of these:
- Naming the drug without active LegitScript + Meta authorization.
- Before/after or “lose X lbs” imagery.
- Negative self-perception or body-shaming framing.
- Pixel or landing-page signals that classify you as an uncertified Rx pharmacy.
- AI-generated testimonials making outcome claims.
The reason this matters so much: a disabled account at $200K/month in spend isn’t a creative problem, it’s a company problem. The recovery timeline is measured in weeks, and your CAC goes to infinity while you wait.
How compliant GLP-1 brands keep scaling
The brands winning right now sell the program and the outcome, not the molecule. That reframe unlocks almost everything:
- Lead with metabolic-health education, not the drug. A “GLP-1 companion program” or “medical weight-loss program” framing keeps you inside policy while still capturing intent.
- Kill the scale and the before/after. Replace transformation imagery with single lifestyle shots, disclaimered testimonials, and problem-aware education (appetite, “food noise,” the science).
- Move the clinical intake off-platform. The eligibility quiz and prescribing flow live on your site, not in the ad.
- If you name the drug, get certified. Complete LegitScript, obtain Meta authorization, geo-restrict to US/CA/NZ, add the consult disclaimer, and gate to 18+.
This isn’t a growth tax. Compliant brands consistently hold lower, more stable CAC than the ones playing whack-a-mole with rejections - because their accounts stay live long enough for the algorithm to learn. See our GLP-1 CAC benchmarks for what “good” looks like, and the GLP-1 growth playbook for the full funnel.
The bottom line
The 35-state-AG action didn’t kill GLP-1 advertising on Meta - it killed lazy GLP-1 advertising. Before/after creative, AI-faked testimonials, and compounded-equivalence claims are now enforcement magnets. Sell the program, keep the drug name off the creative unless you’re certified, and move the clinical work off the ad. That’s the version of this business that survives the crackdown and scales through it.
At AdBoost Health, compliance review is the first gate every GLP-1 creative passes before a dollar of spend touches it - which is exactly why our partners’ accounts don’t get yanked mid-scale.
Sources: Meta ad standards - drugs & pharmaceuticals · Meta ad standards - health & wellness · Google Ads healthcare policy. The state-AG letter and FDA warning letters are public records; policy rules above reflect the platform pages as of July 2026.
